CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study
View Full Paper
Ask AI
Bookmark
Share
Discussion
Loading...
Member takes
Overview
Retrospective analysis finds higher recurrent VTE rates in patients with factor V Leiden and/or prothrombin mutation, suggesting careful management is needed.
Key Points
Patients with factor V Leiden and/or prothrombin gene mutation have higher recurrent VTE rates during DOAC treatment.
Cumulative incidence of recurrent VTE was 16.5% for FVL and 19.4% for PGM compared to 3.3% for wild-type patients.
Treatment duration with DOACs averaged 42 months in patients with thrombophilia and 40 months in those without.
No significant differences in arterial events or bleeding rates were found between thrombophilia and wild-type patients.